Eton Pharmaceuticals, Inc. Financing Cash Flow
Eton Pharmaceuticals, Inc. (ETON) reported Financing Cash Flow of $1.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$76.00K.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $1.39M, a 252.54% increase year-over-year.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $421.00K, a 98.75% decline year-over-year.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $815.00K, a 97.50% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $32.59M.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$957.00K.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$134.00K, a 134.27% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 5 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 8 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.31M 10-Q · filed 2026-08-13 | $1.73M derived: sum of 3 quarters · filed 2026-08-13 | $1.73M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $1.39M 10-Q · filed 2026-05-14 | $1.81M derived: sum of 2 quarters · filed 2026-05-14 | $1.81M derived: sum of 3 quarters · filed 2026-05-14 | $1.81M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $421.00K derived: sum of 2 quarters · filed 2026-03-19 | $421.00K derived: sum of 3 quarters · filed 2026-08-13 | $815.00K 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $394.00K 10-Q · filed 2025-11-06 | $33.97M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $394.00K 10-Q · filed 2026-08-13 | $33.97M derived: sum of 3 quarters · filed 2026-08-13 | $33.58M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $394.00K 10-Q · filed 2026-05-14 | $33.97M derived: sum of 2 quarters · filed 2026-05-14 | $33.58M derived: sum of 3 quarters · filed 2026-05-14 | $33.37M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $33.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $33.19M derived: sum of 2 quarters · filed 2026-03-19 | $32.97M derived: sum of 3 quarters · filed 2026-03-19 | $32.59M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$601.00K derived: sum of 2 quarters · filed 2025-11-06 | -$979.00K 10-Q · filed 2025-11-06 | -$1.27M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-06-30 | -$216.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$594.00K 10-Q · filed 2025-08-07 | -$888.00K derived: sum of 3 quarters · filed 2026-03-19 | -$1.26M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-03-31 | -$378.00K 10-Q · filed 2025-05-13 | -$672.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.04M derived: sum of 3 quarters · filed 2026-03-19 | -$1.29M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2023-12-31 | -$294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$663.00K derived: sum of 2 quarters · filed 2026-03-19 | -$908.00K derived: sum of 3 quarters · filed 2026-03-19 | -$957.00K 10-K · filed 2026-03-19 | |||
| 2023-09-30 | -$369.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$614.00K derived: sum of 2 quarters · filed 2024-11-12 | -$663.00K 10-Q · filed 2024-11-12 | -$564.00K derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-06-30 | -$245.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$294.00K 10-Q · filed 2024-08-08 | -$295.00K 10-Q · filed 2023-08-10 | -$195.00K derived: sum of 3 quarters · filed 2025-03-18 | -$160.00K derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-03-31 | -$49.00K 10-Q · filed 2024-05-09 | $50.00K derived: sum of 2 quarters · filed 2025-03-18 | $85.00K derived: sum of 3 quarters · filed 2025-03-18 | $202.00K derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $134.00K derived: sum of 2 quarters · filed 2025-03-18 | $251.00K derived: sum of 3 quarters · filed 2025-03-18 | -$134.00K 10-K · filed 2025-03-18 | |||
| 2022-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $152.00K derived: sum of 2 quarters · filed 2023-11-09 | -$233.00K 10-Q · filed 2023-11-09 | -$165.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | $117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$268.00K 10-Q · filed 2023-08-10 | -$200.00K derived: sum of 3 quarters · filed 2024-03-14 | -$341.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | -$385.00K 10-Q · filed 2023-05-11 | -$317.00K derived: sum of 2 quarters · filed 2024-03-14 | -$458.00K derived: sum of 3 quarters · filed 2024-03-14 | -$97.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$73.00K derived: sum of 2 quarters · filed 2024-03-14 | $288.00K derived: sum of 3 quarters · filed 2024-03-14 | $391.00K 10-K · filed 2024-03-14 | |||
| 2021-09-30 | -$141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $220.00K derived: sum of 2 quarters · filed 2022-11-10 | $323.00K 10-Q · filed 2022-11-10 | $21.51M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-06-30 | $361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $464.00K 10-Q · filed 2022-08-11 | $21.65M derived: sum of 3 quarters · filed 2023-03-16 | $23.81M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-03-31 | $103.00K 10-Q · filed 2022-05-12 | $21.29M derived: sum of 2 quarters · filed 2023-03-16 | $23.45M derived: sum of 3 quarters · filed 2023-03-16 | $24.24M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2020-12-31 | $21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $23.35M derived: sum of 2 quarters · filed 2023-03-16 | $24.14M derived: sum of 3 quarters · filed 2023-03-16 | $31.63M 10-K · filed 2023-03-16 | |||
| 2020-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | $2.95M derived: sum of 2 quarters · filed 2021-11-16 | $10.44M 10-Q · filed 2021-11-16 | $15.36M derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2020-06-30 | $788.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $8.28M 10-Q · filed 2021-08-16 | $13.20M derived: sum of 3 quarters · filed 2022-03-16 | $13.28M derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2020-03-31 | $7.49M 10-Q · filed 2021-05-13 | $12.41M derived: sum of 2 quarters · filed 2022-03-16 | $12.49M derived: sum of 3 quarters · filed 2022-03-16 | $12.69M derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2019-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $5.00M derived: sum of 2 quarters · filed 2022-03-16 | $5.20M derived: sum of 3 quarters · filed 2022-03-16 | $5.20M 10-K · filed 2022-03-16 | |||
| 2019-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $278.00K derived: sum of 2 quarters · filed 2020-11-12 | $282.00K 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | $201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $205.00K 10-Q · filed 2020-08-12 | |||||
| 2019-03-31 | $4.00K 10-Q · filed 2020-05-14 | ||||||
| 2018-12-31 | $21.96M 10-K · filed 2021-03-16 | ||||||
| 2017-12-31 | $18.00M 10-K · filed 2020-03-05 | ||||||
| 2017-09-30 | $18.00M 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |